Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Cavo, M; Pantani, L; Petrucci, Mt; Patriarca, F; Zamagni, E; Donnarumma, D; Crippa, C; Boccadoro, M; Perrone, G; Falcone, A; Nozzoli, C; Zambello, R; Masini, L; Furlan, A; Brioli, A; Derudas, D; Ballanti, S; Dessanti, Ml; De Stefano, V; Carella, Am; Marcatti, M; Nozza, A; Ferrara, F; Callea, V; Califano, C; Pezzi, A; Baraldi, A; Grasso, M; Musto, P; Palumbo, A; Russo, Domenico; Gimema Italian Myeloma, Network